Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients

Conclusions: Natalizumab modified the expression levels of three miRNAs after a 6-month treatment. We suggest miR-320, miR-320b and miR-629 as possible biomarkers for individual PML risk assessment.

http://msj.sagepub.com/cgi/content/abstract/20/14/1851?rss=1

Source: Multiple Sclerosis - December 17, 2014 Category: Neurology Authors: Munoz-Culla, M., Irizar, H., Castillo-Trivino, T., Saenz-Cuesta, M., Sepulveda, L., Lopetegi, I., de Munain, A. L., Olascoaga, J., Baranzini, S., Otaegui, D. Tags: Research Papers Source Type: research